Regencell bioscience holdings limited announces partial exercise of underwriter's over-allotment option

Hong kong--(business wire)--regencell bioscience holdings limited (nasdaq:rgc) ("regencell" or the "company"), an early-stage bioscience company that focuses on research, development and commercialization of traditional chinese medicine ("tcm") for the treatment of neurocognitive disorders and degeneration, specifically attention deficit hyperactivity disorder ("adhd") and autism spectrum disorder ("asd"), today announced that the underwriter of its initial public offering (the “offering”) had
RGC Ratings Summary
RGC Quant Ranking